Study of Escitalopram in the Treatment of Specific Phobia

Completed · Phase 2/Phase 3

Conditions studied: Phobic Disorders

In brief

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

Key facts

Study ID

NCT00121069

Run by

Connor, Kathryn M., M.D.

People needed

12

Starts

2002-09-01

Expected to finish

2004-09-01

Last updated by the study team

2005-07-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults 18-65 years of age
• DSM-IV criteria for specific phobia according to the MINI
• For women of childbearing potential, a negative serum pregnancy test at screening
• Written informed consent

You may not qualify if…

• Any current primary DSM-IV diagnosis other than specific phobia
• History of DSM-IV substance abuse or dependence within the last months
• Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
• Suicide risk or serious suicide attempt within the last year
• Clinically significant laboratory or EKG abnormality or unstable medical condition
• For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
• Subjects needing concurrent use of psychotropic medications

Where it is running

• Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.